^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    eramkafusp alfa (IGN002)

    i
    Other names: IGN002, IGN-002, IGN 002
    Associations

    News

    Trials
    Company:
    Assertio
    Drug class:
    CD20 inhibitor, IFNα stimulant
    Related drugs:
    Associations

    News

    Trials
    2years
    Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects (clinicaltrials.gov)
    P1, N=62, Terminated, Spectrum Pharmaceuticals, Inc | Recruiting --> Terminated; Strategic Reasons
    Trial termination
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    eramkafusp alfa (IGN002)
    3years
    Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects (clinicaltrials.gov)
    P1, N=62, Recruiting, Spectrum Pharmaceuticals, Inc | Suspended --> Recruiting
    Enrollment open
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    eramkafusp alfa (IGN002)